SARS-CoV-2 nsp13-IN-1

• UNSPSC Description:

  SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent nsp13 (non-structural protein 13) inhibitor. SARS-CoV-2 nsp13-IN-1 only inhibits nsp13 ssDNA+ ATPase, with an IC50 of 6 μM. SARS-CoV-2 nsp13-IN-1 does not inhibit ssDNA- ATPase. SARS-CoV-2 nsp13-IN-1 can be used for COVID-19 research[1].

• Target Antigen:

  SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/sars-cov-2-nsp13-in-1.html

• Solubility:

  DMSO : 41.67 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CC1=NC2=NC=CC=C2C(N1C3=CC=C(C=C3)NC(C4=CC=C(C=C4)C5=CC=CC=C5)=O)=O

• Molecular Weight:

  432.47

• References & Citations:

  [1]Yazdi AK, et al. Kinetic Characterization of SARS-CoV-2 nsp13 ATPase Activity and Discovery of Small-Molecule Inhibitors. ACS Infect Dis. 2022 Jul 13.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1005304-44-8